Amstutz, U.

pharmacogenetic mutation patient cancer pharmacogenomic european medicines agency warfarin allele . med tumor toxicity tacrolimu genotype response variant science cyp 2c *5701 hla-b tamoxifen european saliva sample snps medicine statin gefitinib result university polymorphism /pharmacogenomic presence clopidogrel treatment blood status disease non-small-cell lung cancer future trial cyp 2d activity group cetuximab breast . clin agency study recommendation therapy vkorc liver label esf –ub conference 5- fu results ƒƒ presence report drug-induced liver injury loss-of-function department pharmaco activity indication material pharmacology factor interpretation effect erlotinib warfarin dose sample azathioprine hla-b *5701 breast cancer amstutz institute metastatic genotyping fda – report becquemont indication ƒƒ kras mutations resistance